
Insulet (PODD) Stock Forecast & Price Target
Insulet (PODD) Analyst Ratings
Bulls say
Insulet is a Neutral rating and shares are fairly valued on an EV/sales basis. The company's overreliance on the Omnipod system, which makes up over 98% of their revenue, exposes them to potential cybersecurity risks and recalls, as well as fierce competition in the insulin delivery market. While the recently released Omnipod 5 system may provide a boost to international sales, lower rates of utilization and retention among Type 2 customers in the US could hinder growth for the remainder of the year. Additionally, management credibility has been called into question due to recent missteps and recalls, leaving the company's outlook uncertain and hindering potential for further growth and profitability.
Bears say
Insulet is facing increased pressure and competition from tubed pump competitors, new market entrants, and potential market risks and global inflationary trends. Their efforts to maintain their position as a market leader and increase revenue and margins through new product initiatives and expansion into the Type 2 diabetes market may not be enough to offset potential losses in market share and margin compression.
This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.
Insulet (PODD) Analyst Forecast & Price Prediction
Start investing in Insulet (PODD)
Order type
Buy in
Order amount
Est. shares
0 shares